Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphoma
Clinic will offer Comprehensive Genetic Counselling and Testing Services to empower patients with personalized care
The partnership will capitalize on the combined capabilities of the two organizations
The policymakers, doctors and, patient bodies discuss ways to implement thalassemia control programme nationally
This approval reflects Biocon Biologics' compliance with the highest international regulatory standards
The YP-P10 pre-clinical head-to-head study, jointly conducted by five people including Dr. Kyungho Park of Naason Science
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
The R&D Center significantly increases Siegfried’s R&D capacity to drive further growth
Subscribe To Our Newsletter & Stay Updated
